DOI: 10.1039/d6ra06901k ISSN: 2046-2069
New hemiaminal ether dihydropyrimidinones as CK1/CK2 inhibitors targeting α-synuclein in Parkinson's disease
Hamza Wakeel, Shanza Munir, Humaira Yasmeen Gondal, Zain Maqsood Cheema, Aleena Muskan, Imran Malik, Muhammad Nisar, Hina Siddiqui, Sadaf Khaliq SultanThis study aimed to develop new dihdropyrimidones based inhibitors to slow Parkinson's disease progression by targeting casein kinase CK1, CK2, and α-synuclein receptors.